- Hello, my name is Dr. Amos Levi. I'm an Interventional Cardiologist working in Rabin Medical Centre in Petah Tikva, Israel. So today we'll be discussing the ASTRO-TAVI collaboration study. This is a study dealing with stroke complicating Transcatheter Aortic Valve Implantation.
Importance of the Study
So, stroke is a serious complication of TAVI. We know that rates were in the range of 5 to 6% in the early days of TAVI. And they had since declined to about 2 to 3%, but actually have plateaued more or less on that rate. So it remains a serious issue with TAVI. There is a lot of data regarding risk factors for stroke, but actually we are the first to collect data directly relating to stroke outcomes in respect to severity and then on the interventions directed to treat acute stroke after TAVI.
Study Design and Patient Cohort
So we collaborated with 14 centers in North America, Europe and Israel. And we looked at data from more than 16,000 TAVI procedures. Actually, we identified 387 strokes out of these 16,000 cases. Then we looked at stroke severity and outcomes. Our main outcomes of interest were mortality at one year and then neurological disability scores at 90 days. And then the last thing we looked at interventions to treat acute stroke and their outcomes. So, 39 patients out of the 387 have undergone interventions to treat acute stroke.
Key Findings
So several important findings. Most strokes occurred within 48 hours of TAVI. We've also noticed that there was a direct correlation between stroke severity and survival at one year. So, survival after severe stroke, mortality after severe stroke, was more than 50% at one month. And mortality after mild stroke was about 30% after one year. We also looked at outcomes of neurointervention. So, 39 patients have undergone neurointervention, 26 of them have undergone mechanical thrombectomy and 13 received thrombolytic therapy. And what we've seen was that odds ratio for independent survival at 90 days after neurointerventions were three compared to conservative therapy. So the outcomes were much better. The neurological outcomes were much better with neurointervention as compared to conservative therapy.
Embolic Protection
So I think that the evidence so far for using protection for every TAVI cases are not very strong. I think we still need to identify the population which will benefit from using protection for stroke prevention.
Take-Home Messages for Clinicians
Okay, so I think that in the recent years, we've talked a lot about prevention of stroke after TAVI which is very important. But we have to acknowledge that we cannot eliminate stroke after TAVI completely. There would continue to be strokes after TAVI. So we need to discuss stroke treatment after TAVI and to find better strategies to manage with stroke after TAVI.
Next Steps
I think that our study is mainly thought provoking and the lot of questions that need to be answered. So for example, we need to compare mechanical thrombectomy to thrombolytic therapy. We know that not all centres can offer mechanical thrombectomy and therefore we need to understand whether thrombolytic therapy is effective and safe to treat stroke after TAVI. And then another question is what should be the strategy in centres that don't have an onsite neurointervention service, what should we do? And there's a lot more to study in this field.
Call for Collaboration
So of course, we need more stroke cases to analyse all of these questions. So, we would be very happy if anyone who is interested to join us in that collaboration will contact us and will share their TAVI and stroke cases with us as well.
EuroPCR 2022: Late-breaking Science Video Collection
Published: 13 May 2022
-
Views:
2303
-
Likes:
7
-
Views:
2303
-
Likes:
7
-
Up Next -
3m 53sPart 2 | Session 7 EuroPCR 22: Short-Term Clinical Outcomes of ACURATE neo2™
-
4m 20s
-
2m 18sPart 2 | Session 9 EuroPCR 22: SYNERGY™ Non-inferior to BioMatrix NeoFlex in OCT SORT-OUT VIII
-
5m 9s
-
7m 18sPart 2 | Session 11 EuroPCR 22: Balloon Vs Self-Expanding Valves in Valve-in-Valve TAVI
-
5m 52sPart 2 | Session 12 EuroPCR 22: MitraClip in Atrial Functional Mitral Regurgitation
-
2m 15sPart 2 | Session 13 EuroPCR 22: SCB with Micro-Reservoir Technology in Coronary Lesions
-
4m 46sPart 2 | Session 14 EuroPCR 22: FORWARD PRO Study Shows No Durability Issues After 3 Years
-
4m 25sPart 2 | Session 15 EuroPCR 22: DEB & DES in the Treatment of Diffuse CAD
-
3m 16sPart 2 | Session 16 EuroPCR 22: EASTBOURNE Registry indicates Satefy of Sirolimus-Coated Balloon
-
4m 27sPart 2 | Session 17 EuroPCR 22: JenaValve TAVR System for the Treatment of Aortic Regurgitation
-
7m 7sPart 2 | Session 18 EuroPCR 22: Transcatheter Tricuspid Valve Repair with PASCAL System
-
6m 53s
-
20m 24sPart 1 | Session 1 EuroPCR 22 Late-breaking Science Preview Joost Daemen, Nicolas M Van Mieghem
-
27m 14sPart 1 | Session 2 EuroPCR 22 Late-breaking Science Wrap-Up Nicolas M Van Mieghem, Joost Daemen
-
3m 28sPart 2 | Session 1 EuroPCR 22: AQVA Study Shows Superiority in QFR-Based Virtual PCI Arm Simone Biscaglia
-
5m 10sPart 2 | Session 2 EuroPCR 22: Patient-Level Pooled Analysis of Ultrasound RDN in radiance-HTN SOLO & Trio Ajay J Kirtane
-
7m 50sPart 2 | Session 3 EuroPCR 22: Optimize PRO Interim Analysis Finds New Technique is "Best-in-Class" Kendra J Grubb
-
5m 56sPart 2 | Session 4 EuroPCR 22: MASTER-DAPT Sub-Analysis Shows Consistent Results in Complex PCI Patients Marco Valgimigli
-
3m 34sPart 2 | Session 5 EuroPCR 22: CRUZ-HBR Indicates Use Of Supraflux™ Cruz Stent Is Favourable David Leistner
Overview
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science trials and spotlight questions that could change treatment strategies in interventional cardiology.
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their take on the most anticipated late-breaking science form EuroPCR 2022.
Part 2
Expert Interviews
Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
Faculty Biographies
Transcript